Phanes Therapeutics, Inc.

9:15 AM - 9:30 AM, Wednesday, October 23, 2019 ・ 2nd Floor
Phanes Therapeutics is an emerging leader in innovative discovery research in the immuno-oncology area and eye diseases. Founded in July 2016, Phanes has a leadership team of industry veterans with extensive drug discovery and development experience in the global pharma and biotech companies, including Pfizer, Amgen, and J&J. Our first-in-class molecules include a mAb for solid tumors as well as age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), and a bispecific antibody for small cell lung cancer. Our pipeline also includes humanized single-chain variable fragments (scFv) against multiple tumor-specific antigens that are suitable for constructing CAR-Ts to target solid tumors.
Our mission is to become a source of innovation in the biopharma industry and we are fully committed to delivering robust therapeutic molecules to patients. We will continue to leverage partnerships with companies that have capabilities complementary to ours.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
PT217, PT698
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided